Mod­er­na's Covid-19 vac­cine sales to trail Pfiz­er's to­tal sig­nif­i­cant­ly in 2021 and 2022

Pfiz­er’s and Mod­er­na’s mR­NA vac­cines to pre­vent Covid-19 are of­ten con­sid­ered equals in many re­spects. Both have shown strong pro­tec­tion from the virus, with lim­it­ed side ef­fects or safe­ty con­cerns among the hun­dreds of mil­lions who have now re­ceived them.

But in its sec­ond quar­ter earn­ings call Thurs­day, Mod­er­na re­vealed how the two are di­verg­ing when it comes to vac­cine sales, as Mod­er­na’s ex­pec­ta­tions for 2021 to­tal about $20 bil­lion, based on the ex­pect­ed man­u­fac­ture of be­tween 800 mil­lion and 1 bil­lion dos­es. Pfiz­er said last week it ex­pects about $33 bil­lion in 2021 Covid vac­cine sales on 2.1 bil­lion dos­es, al­though that amount may in­crease to about 3 bil­lion dos­es.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters